Parmax Pharma Ltd — Important, 01-01-1970: Company Update

Parmax Pharma's Independent Directors Committee (IDC) has published its fairness opinion concerning the open offer. Acquirers intend to acquire up to 2.35 Cr equity shares, representing 26.00% of the company's expanded voting capital. This opinion helps public shareholders evaluate the offer, which is a key factor in their decision to participate or not. The IDC's assessment provides an independent view on the offer terms.